Business:
Small Molecules
Drug notes:
Ziftomenib Clin1 AML, 10 efforts Clin0 AML, ALL; KO-2806 3 efforts RD/Clin0 multiple cancers
About:
Kura Oncology is using precision oncology to find cures for cancer patients. By understanding the evolving molecular processes that drive cancer, Kura is pioneering new approaches to treat diseases, including head and neck cancer, lung cancer and acute leukemias. In particular, Kura is gaining a deep understanding of the underlying causes of treatment resistance - this will enable them to design smart combination regimens with other cancer therapies to target tumors from multiple directions, improving the likelihood of success. Important to their approach, Kura is finding novel biomarkers that can be used to stratify patients through the use of precision oncology. Kura’s lead candidate, ziftomenib, is a small molecule drug that is currently being investigated in clinical trials.
Senior Director, Medical & Regulatory Writing Boston, Massachusetts|7 days ago
Executive Assistant San Diego, CA|8 days ago
Assoc Dir/Director, Outsourcing Manager Boston, Massachutsetts|15 days ago
Senior Accountant San Diego, CA|19 days ago
Office & Facilities Administrator San Diego, CA|20 days ago
Assoc Dir/Director, Regulatory Affairs Boston, Massachutsetts|21 days ago
Sr Mgr/Associate Director, GMP Quality Assurance Boston, San Diego, Remote |25 days ago
Executive Director, Medical Affairs Strategy Remote|41 days ago
Chief of Staff Boston, MASS|70 days ago
Associate Director/Director, Biostatistician Boston, San Diego, Remote |100+ days ago